The Claim

SGLT2 is primarily expressed in human epicardial preadipocytes, and its expression level decreases during terminal differentiation into adipocytes.

Source: Empagliflozin suppresses the differentiation/maturation of human epicardial preadipocytes and improves paracrine secretome profile

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
32score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Description
1 study reviewed
In plain English

In human heart fat precursor cells, the SGLT2 protein is present at high levels, and its amount reduces when these cells mature into fat cells.

See the scientific wording

SGLT2 is primarily expressed in human epicardial preadipocytes and its expression decreases upon terminal differentiation into adipocytes.

Why this might work

Heart fat cells start with a protein called SGLT2 that helps them take up sugar. When these cells begin to turn into mature fat cells, they stop making this protein. Without SGLT2, the cells change how they store fat and release fewer inflammatory signals.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Empagliflozin suppresses the differentiation/maturation of human epicardial preadipocytes and improves paracrine secretome profile

    The study found that the SGLT2 protein is mostly found in immature heart fat cells and disappears when those cells turn into mature fat cells — exactly what the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.